Anthony Tolcher MD
Anthony Tolcher, M.D., is founder and CEO of NEXT Oncology, one of the most successful and respected Phase 1 programs in oncology research. Prior to founding NEXT Oncology, Dr. Tolcher was President and Co-Founder of START LLC, one of the world’s largest Clinical Phase I and early drug development operations in cancer medicine. Dr. Tolcher is a medical oncologist with over 25 years’ experience in early drug development and clinical trials and has been involved in more than 21 of the initial Phase 1 studies of new oncology agents that subsequently were FDA approved, including PD-(L)1 inhibitors, antibody-drug conjugates, anti-tumor-associated antigen antibodies, and numerous targeted therapies, and he is currently the principal investigator of over 20 Phase 1 studies. He has over 130 peer‐reviewed publications in scientific journals and has chaired the Developmental Therapeutics Review Committee for ASCO. Dr. Tolcher obtained his M.D. degree from the University of British Columbia and then completed Internal Medicine Residency at the University of Toronto, Oncology Fellowship at the University of British Columbia and a research fellowship at the NCI, Bethesda.